10 Sunesis Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $SNSS | NASDAQ:SNSS | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)Consensus Rating:Buy (Score: 2.67)Consensus Price Target: $11.20 (53.64% upside) Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/5/2014Leerink SwannBoost Price TargetOutperform$14.00 -> $17.00View 2/25/2014Leerink SwannBoost Price Target$10.00 -> $14.00View 1/20/2014ZacksUpgradeNeutral -> Outperform$5.40View 7/31/2013Credit SuisseDowngradeNeutralView 1/15/2013Credit SuisseInitiated CoverageOutperform$7.00View 12/19/2012Wells Fargo & Co.Initiated CoverageOutperformView 10/5/2012Cowen and CompanyReiterated RatingOutperformView 9/21/2012Cowen and CompanyReiterated RatingOutperformView 9/11/2012WedbushReiterated RatingOutperformView 9/11/2012Cantor FitzgeraldReiterated RatingBuy$6.00 -> $8.00View 9/5/2012Leerink SwannInitiated CoverageOutperformView 6/15/2012Cantor FitzgeraldReiterated RatingBuy$6.00View 5/29/2012RBC CapitalUpgradeSector Perform -> Outperform$3.00 -> $5.00View 4/12/2012Cantor FitzgeraldInitiated CoverageBuy$6.00View (Data available from 3/10/2012 forward) Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView 11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView 7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView 5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView 3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView 11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView 8/9/2012($0.20)($0.20)ViewN/AView 5/15/2012($0.18)($0.30)ViewN/AView 11/14/2011($0.18)($0.11)ViewN/AView 8/11/2011($0.15)($0.18)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Sunesis Pharmaceuticals (NASDAQ:SNSS)No insider trades for this company have been tracked by Analyst Ratings Network About Sunesis Pharmaceuticals Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company's VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML. Headlines: (3/6) Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights (3/5) Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher (2/26) Sunesis Announces Proposed Public Offering of Common Stock and Warrants (2/27) Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants (2/11) Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% (3/5) Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape (2/28) Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent ... (2/28) Sunesis to Present at Upcoming Investor Conferences Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: SNSS CUSIP: 86732860 Key Metrics: Previous Close: $7.2550 Day Moving Average: $5.1765200 Day Moving Average: $4.9351 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $394.1MCurrent Quarter EPS Consensus Estimate: $-0.56 EPS Additional Links: View SNSS on Google FinanceView SNSS on Yahoo FinanceView SNSS's Company Profile on ReutersSearch for Sunesis Pharmaceuticals Inc. on Google Sunesis Pharmaceuticals (NASDAQ:SNSS) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.